Traders Buy Large Volume of Call Options on Neumora Therapeutics (NASDAQ:NMRA)

Neumora Therapeutics, Inc. (NASDAQ:NMRA) was the target of some unusual options trading activity on Monday. Stock traders acquired 2,812 call options on the company. This is an increase of 309% compared to the average daily volume of 687 call options.

Key Neumora Therapeutics News

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: Company-released data highlighted a promising signal for NMRA-511 (Alzheimer’s agitation), with effect sizes in a pre-specified population comparable to competing pivotal studies — this is the key clinical upside that investors may view as value-creating if replicated. Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Unusually large options buying: traders purchased ~2,812 call contracts (≈+309% vs. normal), signaling speculative bullish positioning or hedging ahead of upcoming trial readouts. This can amplify intraday moves and suggests elevated short-term interest. Charting a Course for Breakthroughs in Brain Diseases
• Neutral Sentiment: Company reported Q4 results and provided a business update; the press release and call offer more color on pipeline priorities and cash runway but did not materially change guidance. Investors will be watching upcoming KOASTAL study readouts and NMRA-511 follow-up. Q4 Press Release
• Neutral Sentiment: Media coverage framed the quarter as a pipeline-forward update despite share weakness; headlines noted the company “topped” forecasts in some outlets while shares slipped — read the details behind the numbers. Neumora tops Q4 earnings forecasts as pipeline advances, shares slip
• Neutral Sentiment: Full earnings call transcript is available for investors who want management’s tone on enrollment progress, cash runway, and development priorities ahead of Q2 data. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Clinical and analyst reaction risk: KOASTAL-1 (navacaprant in MDD) failed its primary endpoint, prompting at least one analyst downgrade (Strong Buy → Hold). KOASTAL-2/3 remain enrolling with topline expected in Q2 2026, but KOASTAL-1’s failure raises uncertainty about the program’s ultimate success and is a key near-term negative driver. Downgrading After Navacaprant Development Setback
• Negative Sentiment: Small Q4 EPS miss: reported EPS was ($0.35) vs. consensus ($0.34), a minor miss but enough to add selling pressure in conjunction with the clinical uncertainty. Earnings coverage / summary

Insiders Place Their Bets

In other news, insider Paul L. Berns sold 9,819 shares of Neumora Therapeutics stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $3.51, for a total transaction of $34,464.69. Following the sale, the insider directly owned 7,395,185 shares of the company’s stock, valued at approximately $25,957,099.35. The trade was a 0.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders have sold 23,387 shares of company stock worth $82,647. 26.80% of the stock is currently owned by company insiders.

Institutional Trading of Neumora Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Siren L.L.C. increased its position in shares of Neumora Therapeutics by 44.3% during the 4th quarter. Siren L.L.C. now owns 6,288,783 shares of the company’s stock valued at $11,257,000 after purchasing an additional 1,930,500 shares during the period. Millennium Management LLC lifted its holdings in shares of Neumora Therapeutics by 80.1% in the fourth quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock valued at $6,474,000 after buying an additional 1,608,266 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Neumora Therapeutics by 24.2% in the fourth quarter. Renaissance Technologies LLC now owns 1,445,902 shares of the company’s stock valued at $2,588,000 after buying an additional 281,926 shares during the period. Ikarian Capital LLC boosted its stake in Neumora Therapeutics by 10,128.9% during the fourth quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock valued at $2,288,000 after buying an additional 1,265,910 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Neumora Therapeutics by 3.6% during the fourth quarter. Geode Capital Management LLC now owns 1,003,746 shares of the company’s stock valued at $1,797,000 after buying an additional 34,818 shares in the last quarter. 47.65% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Mizuho set a $6.00 target price on Neumora Therapeutics in a research note on Monday, January 5th. Royal Bank Of Canada upgraded shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and lifted their price target for the stock from $4.00 to $7.00 in a research note on Monday, December 1st. Leerink Partners began coverage on shares of Neumora Therapeutics in a report on Monday, January 12th. They issued an “outperform” rating and a $8.00 price target on the stock. William Blair upgraded shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $6.71.

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock opened at $1.93 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.85 and a quick ratio of 6.85. Neumora Therapeutics has a 12 month low of $0.61 and a 12 month high of $3.65. The company has a fifty day moving average price of $2.73 and a two-hundred day moving average price of $2.32. The company has a market cap of $322.48 million, a PE ratio of -1.31 and a beta of 2.46.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Monday, March 30th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Research analysts expect that Neumora Therapeutics will post -1.61 earnings per share for the current year.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.